Kestrel Medical: Terminal Value Against a Patent Cliff
Kestrel Medical Devices derives 68% of its $1,180 million FY2024 revenue from the Kestrel-7 catheter. The core US patent expires at the end of FY2029; a European formulation patent runs to FY2032; a next-generation device is in a 120-patient pivotal trial targeting FY2028 approval with no commercial partner signed. Your ten-year DCF uses a WACC of 8.5%, a 23% tax rate and 3.0% terminal growth, producing an enterprise value of $4.1 billion of which terminal value is 74%. Explicit years 1-5 grow revenue 9% a year; years 6-10 grow 4% a year with EBITDA margin drifting from 26% to 24%. The shares trade at $38 against your $46 target. Your associate argues 3.0% terminal growth is defensible because it is in line with long-run nominal GDP.
1. Is 3.0% terminal growth defensible here? What terminal structure would you use instead?
Read the worked answer
No - and the reason is structural, not arithmetic. A perpetuity growth rate describes a business that has already reached steady state. Kestrel will not be in steady state at the end of year 10: the US patent expires in year 6 of the forecast, the European patent in year 9, and the only offset is a pipeline asset that is not in the explicit forecast at all.
The 3.0% is really doing two jobs: capitalizing the Kestrel-7 base at growth, and implicitly capitalizing a next-generation device that has no approval, no partner and a probability of success well below one. That is the error - an unpriced option is being smuggled into the terminal multiple.
Recommended structure:
- Extend the explicit period through the erosion, not up to it. Model years 6-9 as generic entry: assume the Kestrel-7 base erodes to roughly 30-40% of peak revenue within two to three years of expiry, stabilizes at the eroded level, and carries a lower gross margin (generic price point).
- Value the next-gen device separately and probabilistically. Take a peak sales estimate, apply a probability of technical and regulatory success consistent with Phase 2/3 device benchmarks for that class (commonly 50-70%), discount at a rate reflecting the asset's risk or blend into WACC only if you can defend it, and discount from the launch year. Show it as a distinct line so the reader sees what the terminal value depends on.
- Apply terminal growth of 2.0-2.5% to the stabilized, post-erosion base, not to the pre-cliff base. A mature medical device franchise with a single legacy platform does not grow with nominal GDP.
- State the implicit assumption explicitly: if you keep 3.0%, disclose that the terminal business must already be a diversified post-next-gen portfolio and that the pipeline carries most of the value.
2. Quantify the sensitivity of enterprise value to terminal growth and to WACC. What does that tell you about the recommendation?
Read the worked answer
Terminal value formula: TV = FCF x (1+g) / (WACC - g). PV of TV is 74% of $4.1B = $3.03B.
| Case | TV multiple of FCF | vs base (18.73x) | Change in TV | Change in EV | Implied EV |
|---|---|---|---|---|---|
| g = 3.0%, WACC 8.5% (base) | 18.73x | - | - | - | $4.10B |
| g = 2.0%, WACC 8.5% | 15.69x | -16.2% | -16.2% | -12.0% | $3.61B |
| g = 0.0%, WACC 8.5% | 11.76x | -37.2% | -37.2% | -27.5% | $2.97B |
| g = 2.0%, WACC 9.5% | 13.60x | -27.4% | -27.4% | -20.3% | $3.27B |
EV change = 0.74 x change in TV, because only the terminal component moves.
Implication: a single point of terminal growth is worth $490M, or about 12% of enterprise value - roughly $4 per share on your $8 of upside. Your entire target-price premium over the $38 market price sits inside a 100 bp terminal growth assumption and a 100 bp WACC assumption. That is not a research conclusion; it is a lever.
What to do: the recommendation must be driven by the explicit-period and pipeline work, with the terminal value presented as a sensitivity band rather than a point estimate. If the BUY thesis collapses when terminal growth moves from 3.0% to 2.0% - and it does, from $46 to somewhere near $40 - then the thesis is about the multiple, not the business.
3. Run an exit-multiple cross-check on the terminal value and interpret the gap.
Read the worked answer
Method: value the business at a peer EBITDA multiple in year 10 instead of capitalizing a perpetuity, then discount back.
- Year-10 EBITDA (24% margin per the forecast) = $406M
- Peer median EV/EBITDA for mature device franchises: 11.0x
- Year-10 terminal value = 406 x 11.0 = $4,466M
- Discount factor at 8.5% over 10 years = 1 / 1.085^10 = 0.4423
- PV of terminal value = $1,975M
- Plus PV of explicit years 1-10 free cash flow (the $4.1B less the $3.03B terminal PV) = $1,070M
- Implied enterprise value = $3,045M
Versus $4.1 billion from the perpetuity method - a 26% gap.
Interpretation: the two methods are asking the same question and giving materially different answers. When that happens, the perpetuity assumption is usually the culprit, because a 3.0% growth rate on a declining franchise is doing work the explicit forecast does not support. The exit multiple also embeds the same patent-cliff concern the market will apply in year 10, which is why 11.0x - not the 14-16x a growth device company trades at - is the right exit assumption.
Conclusion: the defensible valuation range is roughly $30-$36 per share (EV $3.0-3.6B) before crediting the pipeline. Your $46 target requires both 3.0% perpetual growth and a favorable pipeline outcome, which is double counting. Take the rating to Hold and re-cut the DCF with an explicit erosion period.